
---
title: '同和药业：原料药米拉贝隆通过CDE审批'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=625'
author: 证券时报网
comments: false
date: Fri, 27 May 2022 17:43:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=625'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300636" style="color: #2f67d1;text-decoration: none;" code="300636" target="_blank">同和药业</a>(300636)5月27日晚间公告，公司原料药米拉贝隆通过CDE审批，表明该原料药已批准在国内上市制剂中使用。米拉贝隆是一种选择性β3－肾上腺受体激动剂，临床用于治疗急迫性尿失禁、尿急、尿频等症状的膀胱过度活动症。</p>

                  
</div>
            